PGEN Stock Overview
Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Precigen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.65 |
52 Week High | US$1.93 |
52 Week Low | US$0.84 |
Beta | 1.72 |
11 Month Change | 7.14% |
3 Month Change | 16.20% |
1 Year Change | 32.00% |
33 Year Change | -69.56% |
5 Year Change | -79.58% |
Change since IPO | -93.33% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Jul 18Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade
May 15Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio
Apr 18Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
Nov 10Precigen names Rutul Shah as chief operating officer
Sep 21Circling Back On Precigen
Aug 23Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Aug 10Precigen Q2 2022 Earnings Preview
Aug 07Precigen to sell Trans Ova Genetics for $170M upfront
Jul 05Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
May 10The Prognosis On Precigen
Jan 05Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Dec 31Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher
Aug 12Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt
Jul 16Shareholder Returns
PGEN | US Biotechs | US Market | |
---|---|---|---|
7D | -12.2% | -0.5% | -1.6% |
1Y | 32.0% | 14.9% | 19.8% |
Return vs Industry: PGEN exceeded the US Biotechs industry which returned 14.4% over the past year.
Return vs Market: PGEN exceeded the US Market which returned 20% over the past year.
Price Volatility
PGEN volatility | |
---|---|
PGEN Average Weekly Movement | 9.8% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: PGEN's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 202 | Helen Sabzevari | precigen.com |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Precigen, Inc. Fundamentals Summary
PGEN fundamental statistics | |
---|---|
Market cap | US$405.13m |
Earnings (TTM) | -US$96.91m |
Revenue (TTM) | US$5.44m |
76.6x
P/S Ratio-4.3x
P/E RatioIs PGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PGEN income statement (TTM) | |
---|---|
Revenue | US$5.44m |
Cost of Revenue | US$56.37m |
Gross Profit | -US$50.93m |
Other Expenses | US$45.98m |
Earnings | -US$96.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.38 |
Gross Margin | -936.35% |
Net Profit Margin | -1,781.72% |
Debt/Equity Ratio | 0% |
How did PGEN perform over the long term?
See historical performance and comparison